If you have not done so already and want to receive the most current updates, follow us by clicking the 'INVEST NOW' button above and look for '❤️' to follow.
"Some of you might already know that we have begun taking steps towards conducting a 'GO-PUBLIC' transaction*. We will continue crowdfunding through this process, and for a successful transition, we aim to raise up to $5 million. Our goal would be to have a valuation of at least $ 70 million in a go- public transaction, up from our current valuation of $52.7 million. At that new valuation, the share price would be at least $1.33, which would be a 33% increase from today's share price of $1.00 per share. Additionally, the company is offering shares at a discount. Act fast to take advantage of this limited-time offer of $0.90 per share."
Disclaimer: *There are many steps for the company to complete prior to being able to go public. We cannot offer any assurances or guarantees that a go-public transaction will be completed, or the timeline for completion of such a transaction, or if a go-public transaction is completed the valuation at which the transaction would occur.
We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted, cell repair, immunotherapy, that promotes the reduction of inflammation for treating neurological diseases, cancer, and such inflammatory lung disorders as Acute Respiratory Distress Syndrome (ARDS).
We are happy to announce that you can now be part of this exciting technology and help make a difference by investing in PhorMed.
After multiple clinical studies RP-323 has been found to be safe and the company is now prepared to enter into the next phase of clinical trials advancing its pipeline in collaboration with two clinical sites in Atlanta Georgia.